SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High – Should You Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price reached a new 52-week high on Monday . The stock traded as high as $4.80 and last traded at $4.8740, with a volume of 5994881 shares trading hands. The stock had previously closed at $4.35.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SELLAS Life Sciences Group has an average rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Stock Performance

The firm has a market capitalization of $575.46 million, a PE ratio of -14.43 and a beta of 2.26. The stock has a fifty day moving average price of $2.14 and a 200-day moving average price of $1.94.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Research analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Activity at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin bought 63,400 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was bought at an average price of $1.59 per share, with a total value of $100,806.00. Following the completion of the transaction, the director directly owned 104,400 shares of the company’s stock, valued at approximately $165,996. The trade was a 154.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of SELLAS Life Sciences Group

Several hedge funds and other institutional investors have recently made changes to their positions in SLS. Axxcess Wealth Management LLC acquired a new position in SELLAS Life Sciences Group during the 3rd quarter valued at about $26,000. BNP Paribas Financial Markets increased its holdings in shares of SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares in the last quarter. Blair William & Co. IL acquired a new position in shares of SELLAS Life Sciences Group during the second quarter valued at about $35,000. ProShare Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group in the 2nd quarter valued at approximately $43,000. Finally, Sei Investments Co. acquired a new stake in SELLAS Life Sciences Group in the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.